Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

commercial and other potential of APD125 and other of Arena's drug candidates; the possibility of APD125 to be a non-scheduled treatment; the relevance of indicators of sleep maintenance; the advancement and content of Arena's pipeline; and other statements about Arena's vision, outlook, strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out- licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward- looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partne
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  Diplomat, the nation,s largest ... of two winners in the 2014 Innovations in ... LLC. The results of the competition were announced ... News. Diplomat was honored as ... & Training program. Through Diplomat University, the company ...
(Date:8/22/2014)... MC Medical, a subsidiary of Mitsubishi Corporation (MCM), ... OH medical device company, have formally agreed to ... visualization system in Japan . It is ... Japan in the latter half of 2015. ... product portfolio in endoscopic surgery market in Japan ...
(Date:8/22/2014)... , Aug. 22, 2014  Mark Riccio, ... (CT) imaging facility, is using the online crowd-funding ... even 5D imaging to researchers and would-be superheros ... asks "What would YOU do if you had ... to researchers and explorers everywhere, from elementary through ...
Breaking Medicine Technology:Diplomat honored as a Top Innovator by Specialty Pharmacy News 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... The regional economy is about to get ... the grow again. The plant will invest $100 ... boost production of the popular Highlander midsize sport utility ... to $4 billion. This step allows Toyota to utilize ... to adjust its product mix to meet changing customer ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... 11 (BIM) deletion in advanced non-small cell lung ... survival (PFS) in epidermal growth factor receptor (EGFR) ... patients. Also, BIM deletion independently predicts overall survival ... protein can activate the programmed cell death also ... deletion has been detected in 12.8% of the ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... organization will leverage Risk MonitorPro, (R) ... patient feedback and adverse events,CAMBRIDGE, MA, ... of healthcare quality and safety software, announced today that ... patient safety and quality of care initiatives. , Named ...
... poised to enter Animal Health Rapid Diagnostics Market with ... Jan. 13 Abaxis, Inc. (Nasdaq: ABAX ... instruments for both the medical and veterinary markets, announced ... Scientific for the manufacturing of a Canine Heartworm Lateral ...
... Association (NEA) awarded its Seal of Acceptance to ... NEA Seal of Acceptance is part of the association,s ... to improve the quality of life for people who ... our criteria for having no irritating ingredients and being ...
... Insurance Reports Job Opportunities for Commissioned Insurance Sales Agents Across the ... ... 2009 -- Despite recent reports by the U.S. Bureau of Labor ... continue throughout 2009, Combined Insurance, a leading provider of supplemental ...
... device can be used in home, rather than hospital, and can ... ... (PRWEB) January 13, 2009 -- MedFaxx has announced ... combines the most used form of electrotherapy in the world clinically ...
... on its recent analysis of the autoimmune disease ... with the 2008 European Frost & Sullivan Excellence ... incorporation of synthetically modified peptides for the validation ... autoimmune diseases and is also looking to adopt ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Leading Insurer Reports Positive Outlook for U.S. Insurance Industry Jobs in 2009 2Health News:Leading Insurer Reports Positive Outlook for U.S. Insurance Industry Jobs in 2009 3Health News:North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential 2Health News:North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential 3Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 2Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 3Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 4
ArcticTemp Upright Freezer -20C. Thick wall insulation keeps your samples colder. Reversible door with magnetic gaskets. 2 shelves and a wire basket. Heavy duty compressor with 5 year warranty....
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... F 250 is a portable system for ... temperature measurements. Temperature compensated pH results can ... probe (ATC) or a 3-in-1 electrode. • ... calibration with Auto-Find automatic buffer recognition for ...
... a highly accurate portable, waterproof system for pH, ... compensated pH results can be obtained when used ... electrode. • This GLP/GMP compliant system includes an ... a computer. Up to 100 data sets can ...
Medicine Products: